Skip to content
Search jobs inside your AI agent. Claude, ChatGPT, Claude Code, Codex, Gemini, Cursor and Grok
Connect

recruiting.ultipro.com/uni1066/6ad34249-5071-46e3-aae0-9968385302ad

NewBe an early applicant

General Chapters – Dosage Forms – Visual Inspection Joint Subcommittee - Expert Advisor

Posted Updated 4 views

Description

2025-2030 Focus:

  • USP <1790> modernization: updating visual inspection guidance, with a PF-ready draft targeted for early 2027.
  • Particle classification: establishing consistent definitions for inherent, intrinsic, extrinsic, intended, and unintended particles, aligned with the Subvisible Particle team.
  • Inspection methods & detectability: addressing visualization limits, threshold studies, manual/automated inspection, test sets, and difficult-to-inspect products.
  • Sampling & acceptance criteria: AQL/acceptance sampling, PPQ sampling, small-batch sampling, and appropriate statistical approaches.
  • Emerging/product-specific challenges: particularly cell & gene therapies, ophthalmics, opaque containers, biologics, and combination/device products.
  • Packaging/device contributions: determining how particles introduced by packaging and delivery systems should be assessed and controlled.
  • Particle identification & investigations: guidance around microscopy, FTIR, Raman, characterization, and root-cause analysis.
  • Clinical risk: improving how particle type, size, source, route of administration, and patient population inform risk, while distinguishing visible-particle risk from subvisible-particle risk.
  • Appearance testing vs. compendial visual inspection: clarifying when an appearance test can use USP <790>-based methods versus when a product can actually claim compliance with <790>.
  • Compounding pharmacies: clarifying application of visual inspection expectations to 503B compounding and related settings.
  • Visible/subvisible alignment: coordinating <1790> with the evolving <1788> framework so

USP uses a coherent approach to particles across the visible and subvisible continuum.

2025-2030 Key Issues:

  • Modernizing USP <1790> and resolving outdated or ambiguous visual-inspection guidance.
  • Particle classification: consistent treatment of inherent, intrinsic, extrinsic, intended, and unintended particles.
  • Particle detectability: effects of size, type, contrast, formulation, container, and inspection conditions.
  • Sampling & acceptance criteria: AQL, PPQ, destructive sampling, and especially small/ultra-small batches.
  • Manual vs. automated inspection: method suitability, validation, test sets, and appropriate use of automated/semi-automated systems.
  • Difficult/emerging products: cell & gene therapies, low-volume products, ophthalmics, opaque containers, and biologics with inherent particles.
  • Particle identification & root-cause analysis: microscopy, FTIR, Raman, and other characterization approaches.
  • Clinical relevance/risk: relating particle identity, size, source, administration route, and patient population to actual risk.
  • Appearance vs. USP <790> inspection: clearly distinguishing general appearance testing from compendial compliance.
  • Visible/subvisible alignment: ensuring the revised <1790> framework aligns with the Subvisible Expert Panel's <1788> work.

Required Expertise:

  • Visual inspection science: manual, semi-automated, and automated inspection; detection probability and Knapp-type studies.
  • Particle science & characterization: visible particle classification, morphology, microscopy, FTIR, Raman, and root-cause identification.
  • Statistics & sampling: AQL, acceptance sampling, PPQ sampling, detection thresholds, and approaches for small batches.
  • Biologics/formulation science: protein aggregates and inherent particles, including challenging or difficult-to-inspect products.
  • Advanced modalities: cell & gene therapy and other low-volume or complex products where conventional inspection approaches may not readily apply.
  • Packaging & device expertise: vials, syringes, stoppers, combination products, container-closure systems, and packaging-related particle generation.
  • Clinical/toxicological risk assessment: translating particle size, identity, source, route of administration, and patient population into meaningful risk.
  • Manufacturing & quality systems: inspection qualification/validation, defect investigations, trending, CAPA, process controls, and lifecycle management.
  • Compendial/regulatory expertise: deep understanding of USP <790>, <1790>, related particulate-matter standards, and expectations for compendial compliance. The subcommittee's major current deliverable is modernization of <1790>.

Skills

Apply

See also